Difference between revisions of "Benralizumab (Fasenra)"
Jump to navigation
Jump to search
m |
|||
| Line 1: | Line 1: | ||
| + | ''No FDA approval for hematology/oncology conditions, at this time.'' | ||
==General information== | ==General information== | ||
Class/mechanism: A humanized monoclonal antibody targeting interleukin-5 (IL-5). | Class/mechanism: A humanized monoclonal antibody targeting interleukin-5 (IL-5). | ||
| Line 5: | Line 6: | ||
*[[Hypereosinophilic syndrome (HES)]] | *[[Hypereosinophilic syndrome (HES)]] | ||
| − | + | ==Patient Drug Information== | |
| − | |||
| − | |||
| − | == Patient Drug Information== | ||
*[https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761070s000lbl.pdf Benralizumab (Fasenra) Package Insert]<ref>[https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761070s000lbl.pdf Benralizumab (Fasenra) Package Insert]</ref> | *[https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761070s000lbl.pdf Benralizumab (Fasenra) Package Insert]<ref>[https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761070s000lbl.pdf Benralizumab (Fasenra) Package Insert]</ref> | ||
| Line 25: | Line 23: | ||
[[Category:FDA approved in 2017]] | [[Category:FDA approved in 2017]] | ||
| + | [[Category:Stub]] | ||
Revision as of 13:04, 8 May 2021
No FDA approval for hematology/oncology conditions, at this time.
General information
Class/mechanism: A humanized monoclonal antibody targeting interleukin-5 (IL-5).
Diseases for which it is used
Patient Drug Information
Also known as
- Brand names: Fasenra